Next quarter’s earnings estimate for CARM is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.23. CARM beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
Next quarter’s earnings estimate for CARM is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.23. CARM beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
CARM Sales Forecast
Next quarter’s sales forecast for CARM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CARM beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
Next quarter’s sales forecast for CARM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CARM beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (NASDAQ: CARM), BioCardia (NASDAQ: BCDA) and Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN)
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral CapitalCarisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (NASDAQ: CARM), BioCardia (NASDAQ: BCDA) and Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN)
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral CapitalCarisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -27.65% per trade.
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -17.85% per trade.
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -89.08% per trade.
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -89.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CARM Analyst Recommendation Trends
Rating
Jul 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
10
11
8
6
4
Sell
0
0
0
0
2
Strong Sell
3
1
3
3
3
total
13
12
11
9
9
In the current month, CARM has received 0Buy Ratings, 4Hold Ratings, and 5Sell Ratings. CARM average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
CARM Stock Forecast FAQ
What is CARM’s average 12-month price target, according to analysts?
Currently, no data Available
What is CARM’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CARM, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CARM a Buy, Sell or Hold?
Carisma Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Carisma Therapeutics’s price target?
Currently, no data Available
What do analysts say about Carisma Therapeutics?
Carisma Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of CARM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.